Q-omics provides the consensus-scored KRT18P17 profile across patient tissues and cancer cell-line models. KRT18P17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT18P17 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, KRT18P17 RNA expression shows 14,053 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where KRT18P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P17 survival associations across molecular data types. KRT18P17 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P17 RNA expression–survival associations across cancer types. High KRT18P17 expression shows unfavorable associations in LUAD, LIHC and PAAD, but favorable associations in KIRP, KIRC and UVM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT18P17 RNA expression.
This table summarizes KRT18P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P17 shows higher tumor expression in COAD, STAD, KIRC, LUAD, BRCA and KIRP. The COAD box plot shows higher KRT18P17 RNA expression in tumor versus normal tissue (log2 FC = +0.733, t-test p < 0.001).
This table shows molecular features associated with KRT18P17 in patient tissues and cancer cell lines. In patient samples, KRT18P17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
